Form 4: Heron Therapeutics Executive Exercises Stock Options

William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, exercised stock options and acquired 3,875 shares of common stock on July 19, 2024.

Summary

• On July 19, 2024, William P. Forbes, the EVP and Chief Development Officer of Heron Therapeutics, exercised restricted stock units.
• This transaction resulted in the acquisition of 3,875 shares of common stock.
• Following the transaction, Forbes directly owns 99,249 shares of common stock and 54,240 restricted stock units.
• The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard insider transaction disclosure and doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The vesting schedule of the restricted stock units (16 equal quarterly installments) is a typical arrangement.
• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring compliance with SEC regulations.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates